Diprafenone for treatment of Wolff-Parkinson-White syndrome

The effect of intravenous (1.5 to 2.0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia. Intravenous application of diprafenone significantly increased atrioventricular nodal condu...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 1989-03, Vol.3 (1), p.73-79
Main Authors: Kunze, K P, Schlüter, M, Geiger, M, Kuck, K H
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Aged
Anti-Arrhythmia Agents - adverse effects
Anti-Arrhythmia Agents - pharmacokinetics
Anti-Arrhythmia Agents - therapeutic use
Atrioventricular Node - drug effects
Electric Stimulation
Electrocardiography
Electroencephalography
Female
Humans
Injections, Intravenous
Male
Middle Aged
Propafenone - adverse effects
Propafenone - analogs & derivatives
Propafenone - pharmacokinetics
Propafenone - therapeutic use
Refractory Period, Electrophysiological - drug effects
Tachycardia - physiopathology
Wolff-Parkinson-White Syndrome - drug therapy
Wolff-Parkinson-White Syndrome - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of intravenous (1.5 to 2.0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia. Intravenous application of diprafenone significantly increased atrioventricular nodal conduction time as well as the effective refractory periods of the right ventricle and the accessory pathway in both the antegrade and retrograde directions. Antegrade conduction block in the accessory pathway occurred in two patients after the dose was increased to 2.0 mg/kg body weight. Intravenous diprafenone suppressed the inducibility of supraventricular tachycardia in two patients, but the tachycardia cycle length was significantly increased in all other patients. Fourteen patients were treated with oral diprafenone, and 11 were asymptomatic during a 17-month follow-up, two of these after the dose had been increased to 375 mg/d. Oral therapy had to be withdrawn in two patients because of adverse gastrointestinal side effects and in one because of recurring bronchospasm.
ISSN:0920-3206
1573-7241
DOI:10.1007/BF01881531